Drug Trial Radar · NCT00352703
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Last checked: Nov 20, 2026Latest source record: Nov 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Apr 2006
Primary completion
Apr 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and for 3 consecutive days after autologous PBSCT for treating oral mucositis in patients with NHL and MM who have received high-dose conditioning chemotherapy.
Conditions
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
Interventions
Kepivance (Palifermin)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).Time frame: Up to 40 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.